<DOC>
	<DOCNO>NCT02611167</DOCNO>
	<brief_summary>The purpose study assess safety , feasibility , efficacy intravenous allogeneic bone marrow-derived mesenchymal stem cell ( MSC ) therapy idiopathic Parkinson 's disease ( iPD ) .</brief_summary>
	<brief_title>Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description>Allogeneic bone marrow-derived mesenchymal stem cell ( MSCs ) deliver intravenously one four dos : 1 x 10 6 MSC/kg , 3 x 10 6 MSC/kg , 6 x 10 6 MSC/kg , 10 x 10 6 MSC/kg body weight population patient idiopathic Parkinson 's disease ( iPD ) . The infusion 1 week baseline visit , follow two screen visit . Patients follow 52 week infusion visit . The safety therapy , well impact therapy rate Parkinson 's disease ( PD ) progression , assess .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Men woman age 45 70 . The 45yearold age cutoff ensure enroll juvenile PD patient . Diagnosis Parkinson disease United Kingdom ( UK ) brain bank criterion include presence 2 cardinal sign PD plus bradykinesia . Diagnosis confirm PI specialist Movement Disorders base medical history , physical neurological exam . Patients asymmetric onset , unilateral symptom negative pull test . ( See Appendix A ) Moderate severe microsmia ( UPSIT &lt; 29 ) . A modified Hoehn Yahr stage 3 less levodopa OFF state . ( See Appendix B ) Diagnosis PD 4 7 year . Robust response dopaminergic therapy ( define great 33 % reduction symptom ( Unified Parkinson 's Disease Rating Scale ; UPDRS ) measure ON medicine state compare OFF state . If subject take central nervous system act medication ( e.g. , benzodiazepine , antidepressant , hypnotic ) regimen must optimize stable 90 day prior screen visit . A stable Parkinson 's disease symptomatic therapy least 90 day prior screen project require additional Parkinson 's disease symptomatic therapy least one year baseline visit . Women childbearing potential require use reliable form contraception 30 day prior baseline visit 6 month final dose study drug . Atypical druginduced Parkinsonism . A UPDRS rest tremor score 3 great limb . A Montreal Cognitive Assessment ( MoCA ) score less 25 . ( See Appendix C ) Clinical feature psychosis refractory hallucination . Uncontrolled seizure disorder , defined seizure within last 6 month . Developmental delay . Chronic kidney disease define glomerular filtration rate ( GFR ) &lt; 50 mL/min/m2 . Hepatic disease alter liver function define alanine transaminase ( ALT ) &gt; 150 U/L T. Bilirubin &gt; 1.6 mg/dl admission . Presence clinically refractory orthostatic hypotension screen baseline visit define great equal 20 mmHg change systolic BP great equal 10 mmHg change diastolic BP sit position stand 2 minute respond medical treatment baseline sit BP le 90/60 . History congestive heart failure , clinically significant bradycardia , presence 2nd 3rd degree atrioventricular block . Pulmonary disease : chronic obstructive pulmonary disease ( COPD ) oxygenrequirement rest ambulation ; moderate severe asthma . Active malignancy diagnosis malignancy within 5 year prior start screen ( Cancer free least 5 year permit ; skin cancer , except melanoma , permit ) . Any diagnosis autoimmune disease immunocompromised state , include chemotherapy administration within last 3 year current immunosuppression define white blood cell ( WBC ) &lt; 3 x 103 cells/ml . History stroke traumatic brain injury . Major surgery within previous 3 month plan ensue 6 month . Clinically significant abnormality Screening Visit laboratory study . History use investigational drug within 30 day prior screen visit . History brain surgery PD . Unable return followup visit clinical evaluation , laboratory study , image evaluation . Substance abuse disorder . Active anticoagulation treatment . Any condition investigator feel would pose significant hazard patient enrol complicate study assessment .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>mesenchymal stem cell</keyword>
</DOC>